Sibrotuzumab

Drug Profile

Sibrotuzumab

Alternative Names: BIBH 1; iodine I 131 monoclonal antibody F19; monoclonal antibody F19; Sibrotuzumab I-131

Latest Information Update: 29 Sep 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim; Ludwig Institute for Cancer Research
  • Developer Boehringer Ingelheim
  • Class Antineoplastics; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Fibroblast activation protein antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Head and neck cancer; Non-small cell lung cancer

Most Recent Events

  • 16 Oct 2003 A study has been added to the Cancer therapeutic trials section
  • 11 Sep 2001 A phase I study has been added to the Cancer pharmacokinetics and adverse events sections
  • 14 Jun 2001 This compound is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top